Cabozantinib, for example, an inhibitor of c-MET and VEGFR2, is being evaluated, in combination with trastuzumab, in HER2 positive BC patients who suffer from brain metastasis[50] [Table 1]. This evidence concerns the gene ERBB2 and breast cancer.